A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The goal of this VA demonstration project is to show that the Brain-computer interface (BCI) technology is a clinically practical and important new communication and control option that can improve the lives of veterans with amyotrophic lateral sclerosis (ALS). The project will test four well-supported hypotheses: (1) that people with ALS who find (or will soon find) conventional assistive technology inadequate can and will use a BCI system for important purposes in their daily lives without close technical oversight, 2) they will continue and even increase this use throughout the period of the study, (3) that BCI use will improve their lives, and 4) BCI will improve the lives of their families and caregivers.
| Condition | Intervention | Phase |
|---|---|---|
|
ALS (Amyotrophic Lateral Sclerosis) |
Device: Brain Computer Interface (BCI) |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | CSP #567 - A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients |
- BCI System Installation [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Facility Support of the BCI Systems [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Economic Impact on the VHA [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- BCI Usage by and Impact on the ALS Patient [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- BCI Impact on the Significant Other and Systems Operator [ Time Frame: 12 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 25 |
| Study Start Date: | September 2011 |
| Estimated Study Completion Date: | August 2014 |
| Primary Completion Date: | February 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Arm 1
All participants will use the BCI System as a means of communication.
|
Device: Brain Computer Interface (BCI)
A Brain Computer interface or BCI records brain signals and analyzes them to derive device commands. BCIs give their users communication and control channels that do not depend on peripheral nerves and muscles.
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- El Escorial "Lab Supported Probable" or more definite diagnosis of ALS.
- Subject has lost the ability to communicate verbally (Score of 0 on Item #1 of the ALSFRS-R).
Exclusion Criteria:
- Non-veteran.
- Subject is unable to communicate with caregiver and study personnel willingness and understanding of the consent form (using their existing method of communication).
- Subject is unable to communicate non-verbally with their significant other and systems operator, or with study personnel.
- Subject is unable to identify one significant other.
- Subject is unable to identify one systems operator (person that agrees to be trained and set up the BCI). This person can be the significant other.
- Significant other and systems operator are unable to indicate willingness and understanding of the consent form, age <18, and do not expect to be with the subject for at least one year.
- Visual acuity uncorrectable to at least 20/80.
- Unable to read and comprehend 6th grade text on a computer screen.
- Subject is not living at home.
- Subject's residence is greater than 100 miles from the participating site.
- Subjects age <18.
- Subject, significant other or systems operator do not have a life expectancy of at least one year.
- In the opinion of the BCI installation team, the home environment is not physically and technologically conducive to the BCI operation and use.
- Subject is unable to demonstrate during the screening phase sufficient EEG interaction for the BCI to operate, i.e. classification rate of 70%. Classification rate is defined as the proportion of correct selections made during the daily calibration period of "copy spelling." Copy spelling data refers to data collected while the subject attends to and selects specific predefined characters.
- Significant other and systems operator are unable to demonstrate during the screening phase sufficient skill to manage the daily set-up and routine operations needed for the subject's basic operation of the BCI.
Contacts and Locations| United States, Connecticut | |
| VA Connecticut Healthcare System West Haven Campus, West Haven, CT | |
| West Haven, Connecticut, United States, 06516 | |
| United States, New York | |
| Albany VA Medical Center Samuel S. Stratton, Albany, NY | |
| Albany, New York, United States, 12208 | |
| United States, North Carolina | |
| Durham VA Medical Center, Durham, NC | |
| Durham, North Carolina, United States, 27705 | |
| United States, Ohio | |
| VA Medical Center, Cleveland | |
| Cleveland, Ohio, United States, 44106 | |
| United States, Rhode Island | |
| Providence VA Medical Center, Providence, RI | |
| Providence, Rhode Island, United States, 02908 | |
| Study Chair: | Robert Ruff, MD PhD | VA Medical Center, Cleveland |
More Information
No publications provided
| Responsible Party: | Department of Veterans Affairs |
| ClinicalTrials.gov Identifier: | NCT00786032 History of Changes |
| Other Study ID Numbers: | 567 |
| Study First Received: | November 4, 2008 |
| Last Updated: | April 17, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by Department of Veterans Affairs:
|
Amyotrophic Lateral Sclerosis Brain Computer Interface (BCI) Lou Gehrig's disease |
Additional relevant MeSH terms:
|
Amyotrophic Lateral Sclerosis Sclerosis Motor Neuron Disease Spinal Cord Diseases Central Nervous System Diseases Nervous System Diseases |
Neurodegenerative Diseases TDP-43 Proteinopathies Neuromuscular Diseases Proteostasis Deficiencies Metabolic Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013